DIVENCE IBR Marker Live
ATC code
Species
Cattle.
Indications
Active immunisation of cattle from 10 weeks of age to reduce virus shedding, hyperthermia and clinical signs of IBR (infectious bovine rhinotracheitis).
Onset of immunity: 3 weeks after completion of the basic vaccination scheme.
Duration of immunity:
6 months after completion of the basic vaccination scheme. 1 year after completion of the re-vaccination scheme.
Dose to be administered and administration route
Intramuscular use.
For use in cattle from 10 weeks of age onwards.
Basic vaccination scheme: administer two doses (2 ml each) with an interval of 3 weeks.
Re-vaccination scheme: one dose of 2 ml should be administered at an interval not longer than 6 months after completion of the basic vaccination scheme.
Subsequent re-vaccination scheme: one dose of 2 ml should be administered at an interval not longer than 12 months.
DIVENCE IBR MARKER LIVE may be used for subsequent re-vaccinations after vaccination with DIVENCE PENTA if there is no further need for protection against BRSV, PI-3 and BVDV.
Method of administration:
Avoid contamination during reconstitution and use. Use only sterile needles and syringes for administration.
Reconstitute the lyophilisate with the corresponding volume of solvent:
Number of doses per vial of lyophilisate | Volume of solvent to be used |
5 doses | 10 ml |
20 doses | 40 ml |
40 doses | 80 ml |
50 doses | 100 ml |
1. Peel the top off the aluminium cap on the vial containing the solvent and withdraw 10 ml of volume.
2. Inject the solvent into the vial containing the lyophilisate.
3. Shake until the lyophilisate is in emulsion. The 5-doses vial is now ready to use.
4. For the 20, 40 and 50 doses vials, once the lyophilisate is in emulsion with the 10 ml of solvent, withdraw all the emulsion obtained from the vaccine vial and inject it into the vial containing the remaining solvent.
5. Shake until the lyophilisate is in emulsion.
The reconstituted vaccine is a white-to-yellow emulsion.
Adverse reactions
Cattle:
Very common (>1 animal / 10 animals treated): | Injection site inflammation1, temperature2 | elevated |
Uncommon (1 to 10 animals / 1,000 animals treated): | Anaphylactic-type reaction3. |
1 A slight to moderate transient injection site inflammation (up to 14 cm of diameter) may be observed, which rapidly decreases in diameter within 2 days and subsides within 2 weeks without treatment.
2 An elevated temperature (mean increase 1.7 ºC, in individual animals up to 2.4 ºC) may occur after vaccination. This increase subsided spontaneously within 3 days. 3 In cases of anaphylactic-type reactions, an appropriate symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
